paracetamol + ibuprofen + metamizol

Paracetamol + Ibuprofen + Metamizol refers to the comparative evaluation of two intravenous analgesic regimens—paracetamol combined with ibuprofen versus paracetamol combined with metamizole—for the management of acute pain. This specific comparison is the focus of a Phase 4 clinical trial (NCT07024199) conducted by the Medical University of Warsaw, targeting pediatric patients with acute pancreatitis. Paracetamol is a non-opioid analgesic and antipyretic that acts primarily through the central nervous system. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis. Metamizole (dipyrone) is a non-opioid analgesic with antipyretic and spasmolytic properties, also involving the inhibition of prostaglandin synthesis and modulation of the endocannabinoid system and descending inhibitory pain pathways. The study aims to establish the efficacy and safety profiles of these multi-modal analgesic strategies in a pediatric population.

Brand names

Paracetamol B. BraunParacetamol KabiIbuprofen B. BraunIbuprofen KabiMetamizol-SFMetamizole KabiPyralgin

Other names

Paracetamol with Ibuprofen vs Metamizole for Pediatric Acute Pancreatitis Pain